DMAC

DiaMedica Therapeutics Inc. [DMAC] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

DMAC Stock Summary

Top DMAC Correlated Resources

DMAC

Top 10 Correlated ETFs

DMAC

Top 10 Correlated Stocks

DMAC

In the News

DMAC Financial details

Company Rating
-
Market Cap
92.24M
Income
-19.38M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
18
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-6.21
Forward P/E
-
PEG
-3.23
P/S
-
P/B
2.01
P/C
-
P/FCF
-6.29
Quick Ratio
21.56
Current Ratio
22.07
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.62
EPS next Y
-
EPS next Q
-
EPS this Y
15.38%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
16.67%
-
-
-
-
SMA20
12.32%
SMA50
18.81%
SMA100
53.73%
Inst Own
-
Inst Trans
-
ROA
-31%
ROE
-41%
ROC
-0.44%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.5-4.75
52W High
+62.75%
52W Low
+551%
RSI
62.22
Rel Volume
1.67
Avg Volume
44.59K
Volume
74.67K
Perf Week
3.66%
Perf Month
13.41%
Perf Quarter
63.16%
Perf Half Y
75.95%
-
-
-
-
Beta
1.741
-
-
Volatility
0.18%, 0.42%
Prev Close
-1.51%
Price
6.51
Change
-2.4%

Something similar

Top by Market Cap
NVDA
ABEC.DE
1YD.DE
V
MIX.JO
Top Correlated ETFs
SPMV
UMAR
UMAY
DIVZ
JDIV
Top Correlated Stocks
CYH
SATS
NVRO
SNFCA
MTTR
Similar Market Cap
PCF
ARQQ
RMAX
IVCBW
CREAL.MX

Company Profile

Healthcare Biotechnology
  • Volume Average 44.59K
  • Market Capitalization 92.24M
  • Employee 18
  • CEO Mr. Dietrich John Pauls MBA
  • Headquarters Minneapolis,MN,US
  • IPO Date 2012-08-03
  • Website https://www.diamedica.com

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.